Cardiovascular Generic Drugs: Prospects and Opportunities to 2012

Date: August 22, 2008
Pages: 186
Price:
US$ 3,140.00
Publisher: Espicom Business Intelligence
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: CD8E8331FFBEN
Leaflet:

Download PDF Leaflet

Cardiovascular Generic Drugs: Prospects and Opportunities to 2012
With a number of first line therapies coming off-patent in the next 5 years the prospects for generic producers are good

Cardiovascular disease is a global problem. In the developed world, its prevalence is linked to our increasingly unhealthy lifestyle, with risk factors including lack of exercise, overweight and obesity, and smoking. It is also linked to diabetes, a condition affecting an increasing number of people worldwide which greatly increases the risk of developing heart disease. The main areas targeted by cardiovascular drugs are high blood pressure and elevated blood cholesterol levels.

While the cholesterol management market remains dominated by statins and fixed-dose combination drugs containing statins, the market for drugs to treat hypertension covers a number of classes, such as beta blockers, ACE inhibitors, angiotensin-II receptor antagonists, calcium channel blockers and alpha blockers. The number of drugs to achieve blockbuster status in this sector runs into double figures and recent patent expiries have been characterised by the launch of multiple generics in this highly competitive market. This trend is likely to continue with, for example, the generic launch of the major anti-hypertensive drug ramipril onto the US market which is anticipated in October 2008.

IN FOCUS...

Statins

The most widely prescribed drugs for cholesterol management are HMG-CoA reductase inhibitors, or statins. In terms of revenue, Pfizer’s Lipitor (atorvastatin) is the largest selling drug of any kind worldwide. Lipitor accounts for around 40% of the market for cholesterol management drugs by value. Without a viable replacement in the pipeline, Pfizer is keen to hold onto its Lipitor revenue for as long as possible. Ranbaxy is equally keen to launch generic atorvastatin in key markets and continues its worldwide patent litigation battle with Pfizer. While Pfizer should be able to fend off generic competition in the US at least until its basic patent expires in March 2010, Lipitor has also been facing competition from multiple entries of generic simvastatin.

Anti-Hypertensives

The global hypertension drugs market is currently valued at around US$38.5 billion. The range of drug classes available to treat high blood pressure contributes to the competitive nature of a market in which there were 13 blockbuster drugs in 2006, with combined sales of US$25.8 billion. While competition among the multinationals is significant in this lucrative segment, the marketplace for generics is equally competitive. Typically, an anti-hypertensive going off patent is highly contested with multiple generic market entrants.

Sales forecasts to 2012 for major products

· Crestor
· Lescol
· Lipitor
· Pravachol/Mevalotin
· Zocor
· Zetia
· TriCor
· Vytorin
· Caduet
· Aprovel/Avapro
· Diovan/Co-Diovan
· Cozaar/Hyzaar
· Micardis
· Atacand
· Benicar/Olmetec
· Norvasc
· Adalat
· Altace/Delix/Tritace
· Accupril
· Coreg
· Seloken/Toprol-XL
· Lotrel

Companies active in the cardiovascular market are reviewed with respect to

· Products
· Financials
· Significant developments

Companies covered:

· Actavis
· Apotex
· Aurobindo Pharma
· Caraco Pharmaceutical Labs
· Dr Reddy’s
· Glenmark
· Impax Laboratories
· InvaGen Pharmaceuticals
· Lupin
· Mylan
· Par Pharmaceutical
· Ranbaxy
· Roxane Laboratories
· Sandoz
· Teva
· Watson
· Zydus Cadila
FOREWORD

EXECUTIVE SUMMARY

CARDIOVASCULAR DISEASE

Mortality
Prevention and Treatment
Drugs in the Pipeline
Competitor Ratio Analysis

CHOLESTEROL AND TRIGLYCERIDES

The Cholesterol Management Drugs Market
Statins
NICE Guidance on the use of statins
Lipitor (atorvastatin)
Patents, Generic Competition & Litigation
US
Canada
Austria
Denmark
Finland
Ireland
Norway
Spain
UK
Australia
Andean Pact countries
Sales Forecast
Clinical Trials
SPARCL
Imaging studies: ILLUSTRATE and RADIANCE
Pfizer’s response to the ASTEROID trial
TNT
ASCOT
ASCOT-LLA (Anglo-Scandinavian Cardiac Outcomes Trial: Lipid-Lowering Arm)
CARDS
IDEAL – atorvastatin versus simvastatin
Atorvastatin+rosiglitazone in diabetic patients
Lescol (fluvastatin)
Patents & Generic Competition
Sales Forecast
Clinical Trials
ALERT
LIPS
Crestor (rosuvastatin)
Patents, Generic Competition & Litigation
Safety Issues
Patient data demonstrate efficacy of Crestor
Sales Forecast
Clinical Trials
ASTEROID
METEOR
MERCURY II
EXPLORER
Effect of rosuvastatin on C-reactive protein and renal function
Crestor in combination with ezetimibe
LDL-C reductions - Crestor versus Pravachol and Zocor
Zocor (simvastatin)
Generic Competition
Sales Forecast
Clinical Trials
SAFARI - simvastatin+fenofibrate
4S
Heart Protection Study
Other Antihyperlipidaemic Agents
Zetia (ezetimibe)
NICE guidance on ezetimibe
Patents, Generic Competition & Litigation
Sales Forecast
Clinical Trials
EXPLORER
Co-administration of ezetimibe+fenofibrate
EASE
TriCor (fenofibrate)
Patents, Litigation & Generic Competition
Lipofen (fenofibrate)
Fenoglide (fenofibrate)
Sales Forecast
Clinical Trials
TriCor (fenofibrate) & WelChol (colesevelam)
Niaspan (niacin)
Patents & Litigation
Sales Forecast
Clinical Trials
Niaspan combined with aspirin
COMPELL
Combination Products
Vytorin (ezetimibe+simvastatin)
FDA issues early communication regarding ongoing review of Vytorin
Patents
Sales Forecast
Clinical Trials
ENHANCE
IMPROVE-IT
Vytorin versus Lipitor (atorvastatin) in Type II diabetes patients
Combined post hoc analysis of three studies
VYVA
Caduet (amlodipine+atorvastatin)
Patents & Generic Competition
Sales Forecast
Clinical Trials
GEMINI AALA
JEWEL
Recent Approval and Drugs in Development
Simcor
Competitor Ratio Analysis
Novelty/rationale for mechanism of action
Proof of concept/clinical data
Management/clinical expertise
Competition within the marketplace
Risks associated with drug development in therapeutic class
Sales Forecast
Clinical Trials
SEACOAST
Tredaptive (niacin+laropiprant)
Competitor ratio analysis
Novelty/rationale for mechanism of action
Proof of concept/clinical data
Management/clinical expertise
Competition within the marketplace
Risks associated with drug development in therapeutic class
Sales Forecast
Clinical Trials
Phase III
Tredaptive co-administered with simvastatin
MK-0524B (simvastatin+niacin+laropiprant)
Competitor ratio analysis
Novelty/rationale for mechanism of action
Proof of concept/clinical data
Management/clinical expertise
Competition within the marketplace
Risks associated with drug development in therapeutic class
Sales Forecast
Clinical Trials
MK-0452B versus atorvastatin
MK-0452B versus MK-0452A+simvastatin
TriLipix (ABT-335)
Competitor ratio analysis
Novelty/rationale for mechanism of action
Proof of concept/clinical data
Management/clinical expertise
Competition within the marketplace
Risks associated with drug development in therapeutic class
Sales Forecast
Clinical Trials
Anacetrapib
Competitor ratio analysis
Novelty/rationale for mechanism of action
Proof of concept/clinical data
Management/clinical expertise
Competition within the marketplace
Risks associated with drug development in therapeutic class
Outlook
Clinical Trials
Phase IIb
Phase I
AEGR-733
Competitor ratio analysis
Novelty/rationale for mechanism of action
Proof of concept/clinical data
Management/clinical expertise
Competition within the marketplace
Risks associated with drug development in therapeutic class
Outlook
Clinical Trials
Phase II
Homozygous Familial Hypercholesterolaemia

HYPERTENSION

The Hypertension Drugs Market
Angiotensin-II Receptor Blockers
Aprovel (irbesartan)
Patents & Generic Competition
Sales Forecast
Clinical Trials
INCLUSIVE
COSIMA
Diovan/Co-Diovan (valsartan/valsartan+HCTZ)
Patents, Generic Competition & Litigation
Sales Forecast
Clinical Trials
NAVIGATOR
AADVANCE
VALUE
Val-HeFT
Cozaar/Hyzaar (losartan/losartan+HCTZ)
Patents & Generic Competition
Sales Forecast
Clinical Trials
LIFE
ELITE II
Micardis/MicardisPlus (telmisartan/telmisartan+HCTZ)
Patents & Generic Competition
Sales Forecast
Clinical Trials
SURGE-2
PRISMA
ONTARGET/TRANSCEND
PROTECTION
PROTECTION Study Programme - AMADEO
PROTECTION Study Programme - DETAIL
PROTECTION Study Programme - ESPRIT
PROTECTION Study Programme - ATHOS
PROTECTION Study Programme - INNOVATION
Atacand (candesartan cilexetil)
Patents & Generic Competition
Sales Forecast
Clinical Trials
HIJ-CREATE
TROPHY
CHARM
DIRECT
Switching from losartan to candesartan cilexetil: an observational study in the UK
Benicar (olmesartan)
Patents & Generic Competition
Sales Forecast
Clinical Trials
MORE
BEST & Treatment of Stage I and Stage II Hypertension Studies
Dihydropyridine Calcium Channel Blockers
Norvasc (amlodipine)
Patents & Generic Competition
Sales Forecast
Clinical Trials
ASCOT
CAFE
Adalat (nifedipine)
Patents & Generic Competition
Sales Forecast
Clinical Trials
TALENT
ACTION
Zanidip (lercanidipine)
Sales Forecast
ACE Inhibitors
Vasotec (enalapril)
Generic Competition
Sales Forecast
Altace/Delix/Tritace (ramipril)
Combinations
Patents & Generic Competition
Sales Forecast
Clinical Trials
Altace+HCTZ
Beta Blockers
Coreg (carvedilol)
OPTIMIZE-HF
Patents & Generic Competition
Sales Forecast
Clinical Trials
MUCHA
COMET
COPERNICUS
Seloken/Toprol-XL (metoprolol succinate)
Patents & Generic Competition
Sales Forecast
Clinical Trials
POISE
Alpha Adreno-Receptor Antagonists
Cardura (doxazosin)
Sales Forecast
Combination Products
Lotrel (amlodipine+benazepril)
Patents & Generic Competition
Sales Forecast
Clinical Trials
ACCOMPLISH
LOGIC, SHIELD and ALERT
Azor (amlodipine+olmesartan)
Zanipress (lercanidipine+enalapril)
Recent Approvals and Drugs in Development
Rasilez/Tekturna (aliskiren)
Competitor Ratio Analysis
Novelty/rationale for mechanism of action
Proof of concept/clinical data
Management/clinical expertise
Competition within the marketplace
Risks associated with drug development in therapeutic class
Sales Forecast
Clinical Trials
ALLAY
Phase III Results
Phase II Results
Bystolic (nebivolol)
Competitor Ratio Analysis
Novelty/rationale for mechanism of action
Proof of concept/clinical data
Management/clinical expertise
Competition within the marketplace
Risks associated with drug development in therapeutic class
Sales Forecast
Clinical Trials
Bystolic in African-American patients with Stage I-II HT
Patients with mild-to-moderate HT
Darusentan
Competitor Ratio Analysis
Novelty/rationale for mechanism of action
Proof of concept/clinical data
Management/clinical expertise
Competition within the marketplace
Risks associated with drug development in therapeutic class
Sales Forecast
Clinical Trials
DAR-201
Cleviprex (clevidipine)
Competitor Ratio Analysis
Novelty/rationale for mechanism of action
Proof of concept/clinical data
Management/clinical expertise
Competition within the marketplace
Risks associated with drug development in therapeutic class
Sales Forecast
Clinical Trials
VELOCITY
ECLIPSE
Ilepatril
Competitor Ratio Analysis
Novelty/rationale for mechanism of action
Proof of concept/clinical data
Management/clinical expertise
Competition within the marketplace
Risks associated with drug development in therapeutic class

CORONARY ARTERY DISEASE

Genetic variations may increase risk of CAD
Angina
Recent Approvals and Drugs in Development
Crestor: first statin to achieve atherosclerosis regression by QCA in a major clinical trial
Ranexa (ranolazine)
Competitor Ratio Analysis
Novelty/rationale for mechanism of action
Proof of concept/clinical data
Management/clinical expertise
Competition within marketplace
Risks associated with drug development in therapeutic class
Sales Forecast
Clinical Trials
Ranolazine in LQT3
MERLIN TIMI-36
ERICA
CARISA
MARISA
Procoralan (ivabradine)
Competitor Ratio Analysis
Novelty/rationale for mechanism of action
Proof of concept/clinical data
Management/clinical expertise
Competition within marketplace
Risks associated with drug development in therapeutic class
Sales Forecast
Clinical Trials
Procoralan versus amlodipine in patients with stable CAD
BEAUTIFUL
Generx (alferminogene tadenovec, Ad5FGF-4)
Competitor Ratio Analysis
Novelty/rationale for mechanism of action
Proof of concept/clinical data
Management/clinical expertise
Competition within the marketplace
Risks associated with drug development in therapeutic class
Clinical Trials
AWARE
AGENT-3, AGENT-4
Experimental Stem Cell Therapy

ATRIAL FIBRILLATION

Current Treatments
Cordarone (amiodarone)
Rythmol (propafenone)
Tambocor (flecainide)
Corvert (ibutilide fumarate)
Tikosyn (dofetilide)
Clinical Trials
DIAMOND
Drugs in Development
Multaq (dronedarone)
Competitor Ratio Analysis
Novelty/rationale for mechanism of action
Proof of concept/clinical data
Management/clinical expertise
Competition within the marketplace
Risks associated with drug development in therapeutic class
Sales Forecast
Clinical Trials
EURIDIS and ADONIS
Pulzium (tedisamil)
Competitor Ratio Analysis
Novelty/rationale for mechanism of action
Proof of concept/clinical data
Management/clinical expertise
Competition within the marketplace
Risks associated with drug development in therapeutic class
Sales Forecast
Clinical Trials
Vernakalant (RSD1235)
Competitor Ratio Analysis
Novelty/rationale for mechanism of action
Proof of concept/clinical data
Management/clinical expertise
Competition within marketplace
Risks associated with drug development in therapeutic class
Sales Forecast
Clinical Trials
ACT 1
ACT 3
Phase IIb study of oral vernakalant

PULMONARY ARTERIAL HYPERTENSION

Tracleer (bosentan)
Sales Forecast
Clinical Trials
COMPASS-1 and EARLY
BUILD Programme
BREATHE-5
Paediatric Study
TRAX PMS
Ventavis (iloprost)
Sales Forecast
Clinical Trials
VISION
STEP
Long-term safety and efficacy
ACTIVE
Revatio (sildenafil)
Sales Forecast
Clinical Trials
Australian Trial in Heart Failure
Thelin (sitaxsentan)
Competitor Ratio Analysis
Novelty/rationale for mechanism of action
Proof of concept/clinical data
Management/clinical expertise
Competition within marketplace
Risks associated with drug development in therapeutic class
Sales Forecast
Clinical Trials
Eisenmenger syndrome – observational data
Long-term treatment
STRIDE-2
STRIDE-2X
STRIDE-4
Letairis/Volibris (ambrisentan)
Competitor Ratio Analysis
Novelty/rationale for mechanism of action
Proof of concept/clinical data
Management/clinical expertise
Competition within the marketplace
Risks associated with drug development in therapeutic class
Sales Forecast
Clinical Trials
ARIES
AMB-222
Viveta (treprostinil)
Competitor Ratio Analysis
Novelty/rationale for mechanism of action
Proof of concept/clinical data
Management/clinical expertise
Competition within the marketplace
Risks associated with drug development in therapeutic class
Clinical Trials
Treprostinil in AERx Essence delivery system
TRIUMPH-1
Inhaled treprostinil as add-on therapy

THROMBOSIS

The Thrombosis Drugs Market
Lovenox (enoxaparin)
Patents & Generic Competition
Sales Forecast
Clinical Trials
ExTRACT-TIMI 25
STEEPLE
SYNERGY
Arixtra (fondaparinux)
Patents & Generic Competition
Sales Forecasts
Clinical Trials
OASIS- 5
OASIS 6
ARTEMIS
FLEXTRA
PEGASUS
Plavix (clopidogrel)
Patents & Generic Competition
Sales Forecast
Clinical Trials
Individualised loading study
BRAVE-3
CHARISMA
ACTIVE
Recent Approval and Drugs in Development
Pradaxa (dabigatran)
Competitor Ratio Analysis
Novelty/rationale for mechanism of action
Proof of concept/clinical data
Management/clinical expertise
Competition within the marketplace
Risks associated with drug development in therapeutic class
Sales Forecast
Clinical Trials
RE-VOLUTION (RE-MODEL, RE-MOBILIZE and RE-NOVATE)
Prasugrel
Competitor Ratio Analysis
Novelty/rationale for mechanism of action
Proof of concept/clinical data
Management/clinical expertise
Competition within marketplace
Risks associated with drug development in therapeutic class
Sales Forecast
Clinical Trials
TRITON-TIMI 38
Early-phase data
Rivaroxaban
Competitor Ratio Analysis
Novelty/rationale for mechanism of action
Proof of concept/clinical data
Management/clinical expertise
Competition within marketplace
Risks associated with drug development in therapeutic class
Sales Forecast
Clinical Trials
RECORD2
RECORD3
Phase ll studies
Apixaban
Competitor Ratio Analysis
Novelty/rationale for mechanism of action
Proof of concept/clinical data
Management/clinical expertise
Competition within the marketplace
Risks associated with drug development in therapeutic class
Sales Forecast
Clinical Trials
Phase II
M118
Competitor Ratio Analysis
Novelty/rationale for mechanism of action
Proof of concept/clinical data
Management/clinical expertise
Competition within the marketplace
Risks associated with drug development in therapeutic class
Clinical Trials
Phase II
Phase I
Abbreviations

SOURCES

Espicom Sources
Others

LIST OF TABLES

Deaths from Ischaemic Heart Diseases in Selected Markets, 2005
Deaths from Acute Myocardial Infarction in Major Markets, 2005
Deaths from Diseases of the Pulmonary Circulation and Other Forms of Heart Disease, 2005
Leading Cardiovascular Drugs by Sales Value, 2006-2007 (US$ Million)
US Patent Expiry for Major Cardiovascular Drugs
Launched Products in Development
Novel Drugs in Development
Competitor Ratio Analysis Summary
Sales of Leading Cholesterol Management Drugs, 2006-2007 (US$ Million)
Sales of Leading Statins, 2003-2007 (US$ Million)
Lipitor Sales, 2003-2012 (US$ Million)
Lipitor US Patents
Lescol Sales, 2003-2007 (US$ Million)
Lescol US Patents
Crestor Sales, 2003-2007 (US$ Million)
Crestor US Patents
Zocor Sales, 2003-2007 (US$ Million)
Zetia Sales, 2003-2007 (US$ Million)
Zetia US Patents
TriCor Sales, 2003-2007 (EUR & US$ Million)
TriCor US Patents
Niaspan Sales, 2003-2007 (US$ Million)
Niaspan US Patents
Vytorin Sales, 2004-2007 (US$ Million)
Vytorin US Patents
Caduet Sales, 2004-2007 (US$ Million)
Caduet US Patents
Drugs in Development for Hypercholesterolaemia and Dyslipidaemia
Sales of Leading Hypertension Drugs, 2006-2007 (US$ Million)
Aprovel/Avapro/Karvea Sales, 2003-2007 (EUR & US$ Million)
Avapro/Avalide US Patents
Diovan/Co-Diovan Sales, 2003-2007 (US$ Million)
Diovan US Patents
Cozaar/Hyzaar Sales, 2003-2007 (US$ Million)
Cozaar/Hyzaar US Patents
Micardis Sales, 2003-2007 (EUR & US$ Million)
Micardis Sales in Japan, 2003-2007 (¥ & US$ Million)
Micardis US Patents
Atacand Sales, 2003-2007 (US$ Million)
Blopress Sales, 2003-2007 (¥ Billion & US$ Million)
Atacand/Atacand Plus US Patents
Benicar/Olmetec Sales, 2004-2007 (¥ Million & US$ Million)
Benicar US Patents
Norvasc Sales, 2003-2007 (US$ Million)
Amlodin Sales, 2003-2007 (¥ Billion & US$ Million)
Adalat Sales, 2003-2007 (EUR & US$ Million)
Adalat US Patents
Zanidip Sales, 2003-2007 (EUR & US$ Million)
Vasotec/Vaseretic Sales, 2003-2007 (US$ Million)
Altace/Delix/Tritace Sales, 2003-2007 (EUR & US$ Million)
Altace US Patents
Coreg/Dilatrend Sales, 2003-2007 (£/CHF & US$ Million)
Coreg US Patents
Seloken ZOK/Toprol-XL Sales, 2003-2007 (US$ Million)
Cardura Sales, 2003-2007 (US$ Million)
Lotrel Sales, 2003-2007 (US$ Million)
Lotrel US Patents
Drugs in Development for Hypertension
Drugs in Development for Atherosclerosis and Coronary Artery Disease
Drugs in Development for Atrial Fibrillation
Drugs in Development for PAH
Tracleer Sales, 2003-2007 (CHF & US$ Million)
Sales of Leading Anticoagulant & Antiplatelet Drugs, 2006-2007 (US$ Million)
Lovenox/Clexane Sales, 2003-2007 (EUR & US$ Million)
Lovenox US Patents
Arixtra Sales, 2004-2007 (£ & US$ Million)
Plavix/Iscover Sales, 2003-2007 (EUR & US$ Million)
Plavix US Patents
Drugs in Development for Thrombosis
List of Figures
Global Sales of Leading Statins, 2003-2007 (US$ Million)
Lipitor Sales, 2003A-2012E (US$ Million)
Lescol Sales 2003A-2012E (US$ Million)
Crestor Sales, 2003A – 2012E (US$ Million)
Zocor Sales 2003A-2012E (US$ Million)
Zetia Sales 2003A-2012E (US$ Million)
TriCor Sales, 2003A-2012E (US$ Million)
Niaspan Sales, 2003A – 2012E (US$ Million)
Vytorin Sales, 2004A-2012E (US$ Million)
Caduet Sales 2004A-2012E (US$ Million)
Simcor Projected Sales, 2008-2012 (US$ Million)
Tredaptive Projected Sales, 2008-2012 (US$ Million)
MK-0524B Projected Sales, 2009-2013 (US$ Million)
TriLipix Projected Sales, 2010-2013 (US$ Million)
Aprovel/Avapro Sales 2003A-2012E (US$ Million)
Diovan/Co-Diovan Sales 2003A-2012E (US$ Million)
Cozaar/Hyzaar Sales 2003A-2012E (US$ Million)
Micardis Sales, 2003A-2012E (US$ Million)
Atacand Sales, 2003A-2012E (US$ Million)
Blopress Sales, 2003A-2012E (¥ Billion)
Benicar/Olmetec Sales 2003A-2012E (US$ Million)
Norvasc Sales, 2003A–2012E (US$ Million)
Amlodin Sales, 2003A-2012E (¥ Billion)
Adalat Sales 2003A-2012E (US$ Million)
Zanidip Sales 2003A-2012E (US$ Million)
Vasotec/Vaseretic Sales 2003A-2012E (US$ Million)
Altace/Tritace Sales 2003A-2012E (US$ Million)
Coreg Sales, 2003A-2012E (US$ Million)
Seloken/Toprol-XL Sales 2003A-2012E (US$ Million)
Cardura Sales 2003A-2012E (US$ Million)
Lotrel Sales, 2003A-2012E (US$ Million)
Rasilez/Tekturna Projected Sales, 2007-2012 (US$ Million)
Bystolic Projected Sales, 2008-2013 (US$ Million)
Darusentan Projected Sales, 2009-2012 (US$ Million)
Cleviprex Projected Sales, 2008-2013 (US$ Million)
Ranexa Sales 2006A-2012E (US$ Million)
Procoralan Sales, 2006E-2012E (US$ Million)
Multaq Projected Sales, 2009E-2014E (US$ Million)
Pulzium Projected Sales 2008E-2013E (US$ Million)
Kynapid Projected Sales 2008E-2013E (US$ Million)
Tracleer Sales, 2003A-2012E (US$ Million)
Ventavis Sales, 2005A-2012E (US$ Million)
Revatio Sales, 2005A-2012E (US$ Million)
Thelin Sales, 2006A-2012E (US$ Million)
Letairis/Volibris Projected Sales, 2008-2012 (US$ Million)
Lovenox Sales, 2003A-2012E (US$ Million)
Arixtra Sales, 2004A-2012E (US$ Million)
Plavix/Iscover Sales, 2003A-2012E (US$ Million)
Pradaxa Projected Sales, 2008-2013 (US$ Million)
Prasugrel Projected Sales, 2008-2013 (US$ Million)
Rivaroxaban Projected Sales, 2009-2014 (US$ Million)
Apixaban Projected Sales, 2010-2014 (US$ Million)
Skip to top


Generic Drug Market in Canada US$ 1,000.00 Nov, 2011 · 65 pages
Booming Generics Drug Market in India US$ 1,000.00 Aug, 2011 · 60 pages
Generic Drugs: World Market 2013-2023 US$ 2,400.00 Nov, 2012 · 149 pages
Booming US Generic Drug Market US$ 1,000.00 Oct, 2010 · 50 pages

Ask Your Question

Cardiovascular Generic Drugs: Prospects and Opportunities to 2012
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: